Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development

Argenx's FB102 has successfully met its primary endpoint in a Phase 2 study for celiac disease, showing a significant change from baseline in the ratio of Vh:Cd (p=0.0176). This study provides the first evidence that blocking CD122 can prevent gluten-induced intestinal damage in celiac patients. Following these results, Argenx plans to advance FB102 into Phase 3 development.